Adjuvant Systemic Therapies in Breast Cancer

Surgical Clinics of North America

Volumn 93, Issue 2, 2013, Pages 473-491

  Hernandez Aya, Leonel F ^a   Gonzalez Angulo, Ana M ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant; Adjuvant chemotherapy; Adjuvant endocrine; Adjuvant HER 2 targeted therapy; Breast cancer

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; IXABEPILONE; KI 67 ANTIGEN; LETROZOLE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; FRACTURE; GENE EXPRESSION; HAZARD RATIO; HORMONAL THERAPY; HUMAN; LYMPH NODE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MASTECTOMY; PACLITAXEL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84875321077     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2012.12.002     Document Type: Review

References (85)

1. DeSantis C., Siegel R., Bandi P., et al. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61(6):408-418.
2. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792.
3. Berry D.A., Inoue L., Shen Y., et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006, (36):30-36.
4. Mincey B.A., Palmieri F.M., Perez E.A. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist 2002, 7(3):246-250.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
6. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2010, 15(Suppl 5):39-48.
7. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874.
8. Bland C.S. The Halsted mastectomy: present illness and past history. West J Med 1981, 134(6):549-555.
9. Valagussa P., Bonadonna G., Veronesi U. Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes. Tumori 1978, 64(3):241-258.
10. Hortobagyi G.N., Buzdar A.U. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995, 45(4):199-226.
11. Schabel F.M. Concepts for systemic treatment of micrometastases. Cancer 1975, 35(1):15-24.
12. Fisher B., Fisher E.R. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966, 122(4):791-798.
13. Fisher B. A biological perspective of breast cancer: contributions of the National Surgical Adjuvant Breast and Bowel Project clinical trials. CA Cancer J Clin 1991, 41(2):97-111.
14. Fisher B., Redmond C., Elias E.G., et al. Adjuvant chemotherapy for breast cancer: an overview of NSABP findings. Int Adv Surg Oncol 1982, 5:65-90.
15. Bonadonna G., Valagussa P., Moliterni A., et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332(14):901-906.
16. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 352(9132):930-942.
17. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93(13):979-989.
18. Fisher B., Dignam J., Tan-Chiu E., et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001, 93(2):112-120.
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R., Davies C., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444.
20. Carlson R.W., Allred D.C., Anderson B.O., et al. Invasive breast cancer. J Natl Compr Canc Netw 2011, 9(2):136-222.
21. Schwartz G.F., Bartelink H., Burstein H.J., et al. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J 2012, 18(4):303-311.
22. Schwartz G.F., Giuliano A.E., Veronesi U., et al. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002, 94(10):2542-2551.
23. Todd J.H., Dowle C., Williams M.R., et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56(4):489-492.
24. Blamey R.W., Ellis I.O., Pinder S.E., et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007, 43(10):1548-1555.
25. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
26. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
27. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
28. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14(5):1368-1376.
29. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
30. Colleoni M., Cole B.F., Viale G., et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010, 28(18):2966-2973.
31. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24(23):3726-3734.
32. Aebi S., Sun Z., Braun D., et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011, 22(9):1981-1987.
33. Viale G., Regan M.M., Maiorano E., et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008, 26(9):1404-1410.
34. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
35. Penault-Llorca F., Andre F., Sagan C., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(17):2809-2815.
36. Hayes D.F. Targeting adjuvant chemotherapy: a good idea that needs to be proven!. J Clin Oncol 2012, 30(12):1264-1267.
37. Tang G., Shak S., Paik S., et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011, 127(1):133-142.
38. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19(4):980-991.
39. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005, 23(12):2716-2725.
40. Mook S., Schmidt M.K., Rutgers E.J., et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009, 10(11):1070-1076.
41. Wishart G.C., Bajdik C.D., Dicks E., et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012, 107(5):800-807.
42. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
43. van't Veer L.J., Paik S., Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005, 23(8):1631-1635.
44. Hornberger J., Alvarado M.D., Rebecca C., et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012, 104(14):1068-1079.
45. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294(8):405-410.
46. Fisher B., Redmond C., Dimitrov N.V., et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989, 320(8):473-478.
47. Martin M., Villar A., Sole-Calvo A., et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003, 14(6):833-842.
48. Fumoleau P., Kerbrat P., Romestaing P., et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003, 21(2):298-305.
49. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21(6):976-983.
50. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23(16):3686-3696.
51. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352(22):2302-2313.
52. Coudert B., Asselain B., Campone M., et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 2012, 17(7):900-909.
53. Martin M., Rodriguez-Lescure A., Ruiz A., et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100(11):805-814.
54. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358(16):1663-1671.
55. Gajria D., Seidman A., Dang C. Adjuvant taxanes: more to the story. Clin Breast Cancer 2010, 10(Suppl 2):S41-S49.
56. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21(8):1431-1439.
57. Shulman L.N., Cirrincione C.T., Berry D.A., et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol 2012, 30(33):4071-4076.
58. Palmieri C., Jones A. The 2011 EBCTCG polychemotherapy overview. Lancet 2012, 379(9814):390-392.
59. Joensuu H., Kellokumpu-Lehtinen P.L., Huovinen R., et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012, 30(1):11-18.
60. Jensen E.V., Jacobson H.I., Walf A.A., et al. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 2010, 99(2):151-162.
61. Singh L., Wilson A.J., Baum M., et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. Br J Cancer 1988, 57(6):612-614.
62. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98(9):1802-1810.
63. Svahn T.H., Niland J.C., Carlson R.W., et al. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. J Natl Compr Canc Netw 2009, 7(2):115-121.
64. Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B., Keshaviah A., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
65. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561):559-570.
66. Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25(19):2664-2670.
67. Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.
68. BIG 1-98 Collaborative Group, Mouridsen H., Giobbie-Hurder A., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(8):766-776.
69. Bliss J.M., Kilburn L.S., Coleman R.E., et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 2012, 30(7):709-717.
70. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008, 26(12):1948-1955.
71. Sanchez-Munoz A., Ribelles N., Alba E. Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. Clin Transl Oncol 2010, 12(9):614-620.
72. Mackey J.R. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?. J Clin Oncol 2011, 29(12):1504-1506.
73. Gnant M., Harbeck N., Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 2011, 6(2):136-141.
74. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
75. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 1995, 159(1):19-27.
76. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
77. Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29(25):3366-3373.
78. Gianni L., Dafni U., Gelber R.D., et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12(3):236-244.
79. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
80. Perez E.A., Suman V.J., Davidson N.E., et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011, 29(34):4491-4497.
81. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27(34):5700-5706.
82. Burstein H.J., Winer E.P. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009, 27(34):5671-5673.
83. Russell S.D., Blackwell K.L., Lawrence J., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010, 28(21):3416-3421.
84. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366(2):109-119.
85. van de Velde C.J., Rea D., Seynaeve C., et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377(9762):321-331.